

# *OPEN SOURCE* **APPROACHES TO PHARMA R&D**



**Tuesday, March 31, 2020**  
**6pm EDT**  
**Virtual dinner**

# Thank you for joining the conversation on open-source approaches to pharma R&D

## HOSTED BY

### **Dr. Ashish K. Jha**

Director, Harvard Global Health Institute  
K.T. Li Professor, Harvard School of  
Public Health  
Professor of Medicine, Harvard Medical  
School

## FEATURING

### **Christopher P. Austin**

Director, NIH's National Center for  
Advancing Translational Sciences

### **Bernard Munos**

Senior Fellow, Faster Cures; Co-  
Founder, Open Source Pharma  
Foundation

### **Rena Conti**

Associate Professor, Boston University  
Questrom School of Business

### **Rajeev Venkayya**

President, Global Vaccine Business  
Unit, Takeda Pharmaceuticals

### **Jaykumar Menon**

Chair and Co-Founder, Open Source  
Pharma Foundation

# Agenda - Introduction

Time	Topic	Description	Lead Discussant
5:55-6:01	Zoom Prep	Greeting to people on call, instructions re Zoom use.	Alina Grenier-Arellano, OSPF
6:02-6:10	Welcome	Today's crisis situation, and the relevance of open source models to public health needs worldwide	Ashish Jha, Director, Harvard Global Health Institute
6:10-6:25	Hello, and What is Open Source Pharma?	<p>Confidentiality: Chatham House rule</p> <p>Virtual Dinner. Not the same as 3 hours together over drinks. Follow-up meeting to be held.</p> <p><b>Open Source Pharma:</b> Problem is well known. Most diseases lack effective therapies. High cost and time of standard pharma approaches.</p> <p><b>OSP approach - Linux for drugs</b> Possible benefit: Faster, cheaper, more affordable, more attuned to health need.</p> <p><b>Description:</b> In one form, virtual early stage discovery + pro bono/distributed wet labs + open source style clinical trials within standard regulation + generics manufacture/distribution.</p> <p>A few words from Chris Austin.</p>	<p>Jaykumar Menon, HGHI/OSPF</p> <p>Chris Austin, Director, NIH's NCATS</p>
6:25-6:30	Open Responses to the Crisis	Considered radical by some just a few weeks ago, open approaches are becoming central	Bernard Munos, OSPF

# Agenda – Strategic Planning

Time	Topic	Description	Lead Discussant
6:30-6:35	What Areas of Focus?	<p>Focus on areas where pharma struggles:</p> <p><b>“Insufficient ROI for traditional model”</b></p> <ul style="list-style-type: none"> <li>· Neglected/tropical</li> <li>· Rare</li> <li>· Biothreat/pandemic</li> </ul> <p><b>“Science overly complex for one organization”</b></p> <ul style="list-style-type: none"> <li>· Difficult diseases, e.g. Alzheimers - no results despite much expenditure</li> </ul> <p><b>Question to group:</b> Does this seem right?</p>	Group
6:35-6:55	What Approaches?	<ul style="list-style-type: none"> <li>· Drug repurposing (Dec 2019 NCATS conference)</li> <li>· Gene therapy (Don Lo from NCATS)</li> <li>· Virtual drug R&amp;D/Massive Open Online Research (MOOR)</li> <li>· Vaccine</li> </ul> <p><b>Question to group:</b> Focus on drug repurposing and MOOR? Or all 4 if feasible?</p>	

# Agenda – Strategic Planning

Time	Topic	Description	Lead Discussant
6:55-7:15	IT Platform	<p>Where does one go to do open source pharma? There needs to be a robust place.</p> <p>Components:</p> <ul style="list-style-type: none"> <li>• Databases (clinical, -omics, molecules, should be interoperable)</li> <li>• Tools (drug discovery software, AI)</li> <li>• UX/Templates</li> <li>• Community (including mentors)</li> </ul> <p><b>Question to group:</b> Is this right? If so, who to make and how? Inside gov't or outside? Hybrid? In which country? Funding-purely philanthropic or gov't? Private sector? Volunteer contributions?</p>	Group
7:15-7:25	Open Discussion		
7:25-7:27	OSP4	These topics may feed into 4th Global Open Source Pharma Conference, in DC, or SF, in 2021, and intervening discussions	Jaykumar Menon, HGHI/OSPF
7:27-7:30	Wrap Up		